AorTech International PLC New Patent Issued (5006T)
July 04 2018 - 1:00AM
UK Regulatory
TIDMAOR
RNS Number : 5006T
AorTech International PLC
04 July 2018
4 July 2018
AorTech International plc
("AorTech" or the "Company")
New Patent Issued
AorTech is pleased to announce that the Brazilian Patent Office
has recently granted Patent Number PI 0711694-2 entitled Biostable
Gels. The invention relates to biostable gels, the processes for
their preparation and their use in the manufacture and repair of
biomaterials and medical devices or implants, in particular soft
tissue implants such as breast implants.
Bill Brown, Chairman of AorTech said: "The issue of this patent
further expands AorTech's patent portfolio, particularly in the
area of breast implants. Brazil is one of the largest markets for
breast enhancement outside of the USA and is therefore an important
patent territory. The portfolio of IP relating to Breast Implants
is not currently licensed by AorTech."
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Chairman
Stockdale Securities Limited Tel: +44 (0)20 7601 6100
Tom Griffiths/David Coaten
About AorTech:
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM) the world's leading long-term
implantable co-polymers, now manufactured on their behalf by
Biomerics LLC in Utah, USA. With several million implants and seven
years of successful clinical use, AorTech polymers are being
developed and used in cardiology and urological applications,
including pacing leads, cardiac cannulae, stents and neuro
stimulation devices. Devices manufactured from AorTech polymers
have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA
and Japanese Ministry of Health approvals.
Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to
silicone while exhibiting excellent mechanical, blood contacting
and flex-fatigue properties. These polymers can be processed using
conventional thermoplastic extrusion and moulding techniques. A
range of materials in a variety of application-specific
formulations for use in medical devices and components are
available.
In addition to the licensing of biostable polymers, AorTech is
now developing medical devices utilizing the key properties of its
world class polymers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDLLFERDVIVIIT
(END) Dow Jones Newswires
July 04, 2018 02:00 ET (06:00 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2024 to May 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From May 2023 to May 2024